Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protease, serine, 1 (trypsin 1) | References | |
Homo sapiens | kallikrein B, plasma (Fletcher factor) 1 | Starlite/ChEMBL | References |
Homo sapiens | Coagulation factor VII/tissue factor | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor VII (serum prothrombin conversion accelerator) | References | |
Homo sapiens | protease, serine, 2 (trypsin 2) | References | |
Homo sapiens | protease, serine, 3 | Starlite/ChEMBL | References |
Homo sapiens | protein C (inactivator of coagulation factors Va and VIIIa) | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor III (thromboplastin, tissue factor) | References | |
Homo sapiens | coagulation factor X | Starlite/ChEMBL | References |
Homo sapiens | kallikrein 1 | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor II (thrombin) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 3 | 261 aa | 234 aa | 25.2 % |
Brugia malayi | Trypsin family protein | kallikrein 1 | 262 aa | 247 aa | 22.7 % |
Brugia malayi | Trypsin family protein | protease, serine, 1 (trypsin 1) | 247 aa | 287 aa | 21.6 % |
Echinococcus granulosus | glycoprotein Antigen 5 | coagulation factor VII (serum prothrombin conversion accelerator) | 466 aa | 384 aa | 23.7 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 2 (trypsin 2) | 247 aa | 240 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | PAN domain-containing protein | 0.0356 | 0.9521 | 0.5 |
Echinococcus granulosus | enteropeptidase | 0.0096 | 0 | 0.5 |
Onchocerca volvulus | 0.0369 | 1 | 1 | |
Echinococcus multilocularis | Mastin | 0.0096 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0356 | 0.9521 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0369 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0369 | 1 | 0.5 |
Onchocerca volvulus | 0.0319 | 0.8163 | 0.7669 | |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0369 | 1 | 1 |
Echinococcus granulosus | glycoprotein Antigen 5 | 0.0096 | 0 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0369 | 1 | 1 |
Echinococcus multilocularis | glycoprotein Antigen 5 | 0.0096 | 0 | 0.5 |
Echinococcus granulosus | Mastin | 0.0096 | 0 | 0.5 |
Echinococcus multilocularis | enteropeptidase | 0.0096 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
2PT (functional) | = 0.42 uM | Anticoagulant activity in F7-deficient human plasma assessed as concentration required to double prothrombin time | ChEMBL. | 26151189 |
Ki (binding) | = 0.7 nM | Inhibition of human recombinant TF/F7a complex using S2288 as substrate preincubated for 15 mins followed by protein addition measured for 60 mins | ChEMBL. | 26151189 |
Ki (binding) | = 41 nM | Inhibition of human APC measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 50 nM | Inhibition of human plasma kallikrein using S2302 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 58 nM | Inhibition of human trypsin measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 180 nM | Inhibition of human thrombin using S2238 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 1900 nM | Inhibition of human tissue kallikrein 1 measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 5500 nM | Inhibition of human F10a using S2222 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 34000 nM | Inhibition of human F9a measured for 30 mins | ChEMBL. | 26151189 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.